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Introduction: Neuromyelitis optica is a demyelinating disease of the central nervous system with various patterns
of brain lesions. Corpus callosum may be involved in both multiple sclerosis and neuromyelitis optica. Previous case
reports have demonstrated that callosal lesions in neuromyelitis optica are usually large and edematous and have a
heterogeneous intensity showing a “marbled pattern” in the acute phase. Their size and intensity may reduce with
time or disappear in the chronic stages.
Case presentation: In this report, we describe a case of a 25-year-old Caucasian man with neuromyelitis optica
who presented clinically with optic neuritis and myelitis. His brain magnetic resonance imaging demonstrated linear
enhancement of the corpus callosum. Brain images with contrast agent added also showed linear ependymal layer
enhancement of the lateral ventricles, which has been reported in this disease previously.
Conclusions: Linear enhancement of corpus callosum in magnetic resonance imaging with contrast agent could
help in diagnosing neuromyelitis optica and differentiating it from other demyelinating disease, especially multiple
sclerosis.
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Neuromyelitis optica (NMO) is a severe demyelinating
disease of the central nervous system characterized by
optic neuritis and transverse myelitis. The etiology is un-
known, but anti-aquaporin 4 (AQP4) receptor immuno-
globulin G (IgG) antibody plays an important role in the
pathogenesis of the disease. Based on 2006 criteria, diag-
nosis of NMO requires the presence of optic neuritis
and myelitis plus the presence of at least two of the fol-
lowing three characteristics [1]: (1) a contiguous spinal
cord lesion, visualized by magnetic resonance imaging
(MRI), extending over three or more vertebral segments;
(2) MRI criteria not satisfying the revised McDonald
diagnostic criteria for multiple sclerosis (MS) [2]; and/or
(3) NMO-IgG in serum.
Several studies and case series have shown different
patterns of brain involvement in NMO, which include* Correspondence: msahari@sina.tums.ac.ir
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tricular regions, as well as extensive lesions in the cere-
bral white matter. The corpus callosum has been
reported to be involved in NMO in a pattern different
from that of MS, such as large edematous lesions or in-
volvement of the callosal edge in a linear pattern. Linear
enhancement of the ventricular ependyma has been re-
ported previously as having a “pencil-thin” appearance
[3, 4]. In this report, we present a case of a patient with
NMO with special MRI features of linear enhancement
of the corpus callosum and a pencil-thin appearance in
the ventricular ependymal layer.
Case presentation
Our patient was a 25-year-old Caucasian Iranian man
who was referred to our center in 2010 for further evalu-
ation of paraparesis and urinary incontinence. There was
no significant point in his past medical or familial med-
ical history. He was well until 2008, when he developed
blurred vision in his right eye and was admitted to a
local center with the clinical impression of optic neuritis.article distributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
. The Creative Commons Public Domain Dedication waiver (http://
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5 days without a good response. Two months later he ex-
perienced optic neuritis in his left eye, but he had a good
recovery after receiving intravenous methylprednisolone.
According to his medical records, his physical examin-
ation was normal at that time, with the exception of mild
optic atrophy of the right eye. Brain MRI was performed,
which revealed some hyperintense T2-weighted lesions
around the ventricles, with linear callosal involvement.
The lesion was nicely enhanced in a linear pattern in a
T1-weighted image with contrast agent (Figs. 1 and 2).
Linear enhancement of ventricular surfaces (pencil-thin
appearance) in both the frontal and occipital horns was
another important finding in this patient.
The patient was diagnosed with MS and received inter-
feron (IFN) beta 1a three times per week. Six months later
he developed another episode of optic neuritis in his left
eye, and he had a less than 50 % recovery with intravenous
steroids and plasmapheresis. After 1 year, he developed
paraparesis and urinary incontinence while receiving IFNFig. 1 T2-weighted and T1-weighted images with contrast agent. a,b Imag
c,d Thin ependymal enhancement of lateral ventricular surfaces (pencil-thinbeta 1a three times per week. He was admitted to a local
hospital and received intravenous methylprednisolone
1000mg/day for 5 days. He responded to this therapy
and was able to walk in 4 weeks. At that stage, the pa-
tient was referred to our center to escalate the disease-
modifying therapy.
A neurologic examination of the patient revealed bilat-
eral optic atrophy, weakness of both lower limbs (grade
4/5) and bilateral Babinski sign. Although we did not
perform detailed neuropsychological tests, the patient
did not show any apparent decrease in cognition or any
other signs or symptoms of callosal involvement. New
MRI showed a longitudinal cord lesion extending more
than four vertebral segments without any enhancement.
Regarding episodes of optic neuritis, longitudinal exten-
sive spinal cord lesion and atypical callosal involvement,
anti-AQP4 was checked, and the result was positive.
Other laboratory tests, such as anti-nuclear antibody
and anti-phospholipid antibody, for collagen vascular
diseases were negative. The patient was diagnosed withes show involvement of the corpus callosum with linear enhancement.
ependymal enhancement)
Fig. 2 Axial fluid-attenuated inversion recovery magnetic resonance image of the patient shows hyperintense lesions around the ventricles and
corpus callosum
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50mg/day with a gradual increase to 150mg/day.
Discussion
NMO is one of the most important mimics of MS. Al-
though NMO has distinct immunopathogenesis and treat-
ment options, both NMO and MS may have similar
clinical presentations and imaging features. It is very im-
portant to differentiate NMO and MS, especially in pa-
tients with both optic nerve and spinal cord involvement,
as some MS therapies can exacerbate NMO. MRI may
play an important role in differentiating these two entities.
Spinal cord lesions extending over three or more ver-
tebral segments are typical imaging findings in NMO.
These longitudinal extensive cord lesions are not specific
and can be observed in patients with MS or acute dis-
seminated encephalomyelitis.
Brain MRI scans are usually normal or demonstrate
non-specific T2-weighted hyperintense abnormalities.
These non-specific small hyperintensities are usually
asymptomatic and located in the subcortical or deep
white matter area.Authors of recent case series have reported different
patterns of brain involvement in NMO, especially in areas
with high AQP4 expression. Diencephalic lesions sur-
rounding the third ventricles and cerebral aqueduct,
which include the thalamus, hypothalamus and anterior
border of the midbrain, have been reported in NMO.
These lesions frequently are asymptomatic, but syndromes
of inappropriate anti-diuretic hormone secretion, narco-
lepsy and hypothermia are some of the clinical manifesta-
tions related to these lesions. Lesions located in the dorsal
brain stem adjacent to the fourth ventricle (especially area
postrema) represent one of the most specific brain MRI
abnormalities in patients with NMO and may cause in-
tractable hiccups and vomiting [5].
NMO may involve the corpus callosum in the acute
phase with large edematous lesions and heterogeneous
intensity, higher in the rim and lower in the core of the
lesions (in a “marbled pattern”). Callosal lesions may in-
volve the complete thickness of splenium in a unique
pattern that is called an arch bridge sign [3, 6]. MS typic-
ally and frequently involves the corpus callosum. Lesions
in MS are small, discrete, ovoid and perpendicular to the
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sum. Patients with NMO who have such lesions may be
misdiagnosed with MS. This happened to our patient,
who was treated with IFN beta 1a for 2 years. It is import-
ant for clinicians to know that callosal lesions by them-
selves are not sufficient to differentiate NMO from MS.
Extensive, confluent, hemispheric, T2-weighted lesions
mimicking tumors are more frequent in the pediatric
population. These lesions differ from those observed in
regions of high AQP4 expression and are likely related
to vasogenic edema and sometimes look like “spilled
ink” on MRI scans. Such large lesions may follow the
white matter tracts without severe mass effect and may
cause hemiparesis, encephalopathy and visual field de-
fects [3, 5, 6].
Different patterns of enhancement have been reported
to be typical for NMO, such as multiple patchy enhance-
ments with blurred margins in adjacent regions (cloud-
like pattern) or linear enhancement of the ependymal
surface of the lateral ventricular caps (pencil-thin ap-
pearance). Ito and colleagues showed a cloud-like pat-
tern in 90% of their patients with NMO who had
contrast-enhanced lesions visualized by MRI [7].
Our patient presented with recurrent optic neuritis
and myelitis, which raised the possibility of a diagnosis
of NMO or MS. Involvement of the corpus callosum
misled the clinician to diagnose the patient with MS and
to start MS therapy. Although linear involvement of the
corpus callosum and pencil-thin-appearing enhancement
of ventricular caps in a patient with optic neuritis could
have raised the possibility of NMO, it was ignored at
first, and the diagnosis was delayed until the patient de-
veloped a longitudinal extensive cord lesion.
To the best of our knowledge, this is the first case report
of linear callosal enhancement visualized by MRI. Another
interesting neuroimaging feature of this patient is the sim-
ultaneous enhancement of the corpus callosum and ven-
tricular surfaces in both the frontal and occipital horns.
Conclusions
Special types of enhancement previously reported in the
literature and the pattern we present in this case report
can assist clinicians in differentiating NMO from MS at
an early stage and prevent inappropriate treatments. We
suggest that clinicians pay special attention to brain MRI
of patients who present with optic neuritis and have a
poor response to steroids, as well as of patients with ex-
tensive cord lesions with atypical brain involvement.
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